New radiation schedule could cut treatment time for throat cancer patients
NCT ID NCT06080503
First seen Dec 10, 2025 · Last updated Jun 22, 2026 · Updated 29 times
Summary
This phase II trial compares a new, shorter radiation schedule (LT-SABR, given over 1-2 weeks) to standard radiation (over 5-6 weeks) for early-stage laryngeal cancer. The goal is to see if the shorter schedule causes fewer severe side effects in the first 3 months. About 67 adults with stage 0-II glottic laryngeal cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Texas Southwestern Medical Center
RECRUITINGDallas, Texas, 75390, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Radiation therapy (LT-SABR or IMRT)
What this could lead to
If successful, this could offer a shorter, more convenient radiation schedule with fewer acute side effects for people with early-stage laryngeal cancer.
What could go wrong
This is a small, early-phase study (67 participants) comparing two radiation approaches, so results may not apply broadly. The higher-dose schedule could also increase long-term risks.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.